Cambridge Investment Research Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$273K	Buy	+3,300	New	+$265K	﹤0.01%	3281
2023 Q1	–	Sell	-5,325	Closed	-$214K	–	3154
2022 Q4	$214K	Buy	+5,325	New	+$200K	﹤0.01%	2697
2019 Q2	–	Sell	-3,000	Closed	-$212K	–	2209
2019 Q1	$212K	Buy	+3,000	New	+$176K	﹤0.01%	2033

Other funds holding ANIP

MMA

Mizuho Markets Americas New York $6.37B AUM 47.14% 1-Year Est. Return

MCM

Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

ETC

Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Cambridge Investment Research Advisors's ANIP Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in ANI Pharmaceuticals (ANIP) in Q2 2026: 3,300 shares worth $273K. The stake represents ﹤0.01% of the portfolio and ranks #3281 among its holdings. This is a return to the name: Cambridge Investment Research Advisors previously reported a position in ANIP as recently as Q4 2022.

Cambridge Investment Research Advisors first reported a position in ANIP in Q1 2019 and has held it in 3 quarters since. 43 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

Cambridge Investment Research Advisors held 3,300 shares of ANI Pharmaceuticals worth $273K as of Q2 2026.
ANI Pharmaceuticals was a new Cambridge Investment Research Advisors position in Q2 2026.
ANI Pharmaceuticals made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3281 holding.
Cambridge Investment Research Advisors first reported a position in ANI Pharmaceuticals in Q1 2019 and has held it in 3 quarters since.
43 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.